Yearly Archives: 2022
MDUFA V Agreement Reached
The FDA and representatives from the medical device industry have reached an agreement on proposed recommendations for MDUFA V. On March 22, FDA sent the commitment letter to Congress. Under the new agreement, the FDA would be authorized to collect at least $1.78 billion in user fees over five years. FDA could receive additional funding […]
Pfizer’s $7B bet delivers phase 3 success, advancing bid to establish new drug in ulcerative colitis Arena
Pfizer’s $6.7 billion bet on Arena Pharmaceuticals has delivered a phase 3 success.
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2021 Financial Results
Recursion reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2021.
FierceBiotech recognizes Recursion as the #2 Biotech IPO of 2021!
FierceBiotech Special Report: The top 10 biotech IPOs of 2021
Co-Diagnostics Reports Full Year 2021 Financial Results
Achieved Record Full Year Revenue of $97.9 Million; Strength in Sales Momentum Provides Foundation to Achieve Solid FY’22
WATCH THE EXIM BANK & STEP GRANT FUNDS 101 WEBINAR REPLAY
WTC UTAH HAS A RECORD $1M+ TO ADMINISTER TO UTAH SMALL BUSINESSES. Learn from World Trade Center Utah, Meridian Finance Group, and the U.S. Small Business Administration (SBA) about export programs through the Export-Import Bank of the United States (EXIM) and how State Trade Expansion Program (STEP) funds can be used for those programs as a new eligible expense.
Co-Diagnostics, Inc. Makes Strategic Additions to Scientific Advisory Board
Co-Diagnostics, Inc. Makes Strategic Additions to Scientific Advisory Board
Myriad Genetics Named to Fast Company’s Annual List of World’s Most Innovative Companies
Myriad to establish new Walter Gilbert Research and Innovation Center Company also cited among 2022 Top Workplaces USA National List by Energage
Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Cancer
BRACAnalysis CDx is now the only germline test approved by FDA as a companion diagnostic for treatment of HER2 negative high-risk early-stage breast cancer
Myriad Genetics Advances Precision Oncology with New Precise™ Solutions, Combines Genetic Insights from Multiple Tests to Guide Treatment Decisions and Improve Patient Care
Company launches Precise™ Tumor test, part of a comprehensive suite combining germline, tumor and companion diagnostics in one easy-to-access solution
Pfizer Completes Acquisition of Arena Pharmaceuticals
Acquisition offers new, differentiated, and potentially best-in-class approach to address needs of a broader number of patients with immuno-inflammatory diseases
PolarityTE Announces $5.0 Million Registered Direct Offering
PolarityTE Announces $5.0 Million Registered Direct Offering
